0001193125-13-342179.txt : 20130821 0001193125-13-342179.hdr.sgml : 20130821 20130821160506 ACCESSION NUMBER: 0001193125-13-342179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130819 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20130821 DATE AS OF CHANGE: 20130821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMBIT BIOSCIENCES CORP CENTRAL INDEX KEY: 0001131543 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330909648 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35919 FILM NUMBER: 131052912 BUSINESS ADDRESS: STREET 1: 11080 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8583342100 MAIL ADDRESS: STREET 1: 11080 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d586901d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 19, 2013

Date of Report (Date of earliest event reported)

 

 

Ambit Biosciences Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35919   33-0909648

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

11080 Roselle St.

San Diego, California

  
92121
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 334-2100

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On August 19, 2013, Joseph Regan notified Ambit Biosciences Corporation (the “Company”) of his resignation from the Board of Directors of the Company, effective immediately.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Ambit Biosciences Corporation
Dated: August 21, 2013      
    By:  

 /s/ ALAN FUHRMAN

      Alan Fuhrman
      Chief Financial Officer